PUBLICATION

Drugs & Medical Devices

Get ready for the next wave of pharmaceutical litigation with HarrisMartin's Drugs & Medical Devices. This reporter will keep you one step ahead of drug and medical device litigation with in-depth investigations, guest commentaries and objective courtroom coverage on today's and tomorrow's hottest drugs and supplements.


PUBLICATION ARCHIVES

SEARCH THE ARCHIVES

Issue #96, December 2009

Claims Against Generic Drug Maker are Not Preempted, Judge Rules

State law failure-to-warn claims brought against the manufacturer of a generic form of Reglan are not preempted by federal law


Federal Judge Refuses to Transfer Paxil Suicide Case

In a Paxil suicide case, a federal judge has denied the plaintiff's motion to transfer venue to New York federal court, ruling that


JPML Consolidates Generic Aredia Claims in New York Federal Court

The Judicial Panel on Multidistrict Litigation has consolidated claims in nine product liability cases against the manufacturers of the generic version of


Punitive Damage Claims Do Not Raise Federal Issues, Judge Rules

A federal judge has remanded to state court six Elidel and Protopic injury actions, ruling that the punitive damage claims do not raise federal issues


Elidel, Protopic Injury Case Remanded to State Court

A federal judge has adopted a magistrate judge's recommendation that Protopic and Elidel injury claims against two drug manufacturers be remanded


Issue #95, November 2009

Zyprexa Injury Claims are Time-Barred, Federal Judge Rules

A lawsuit brought against Eli Lilly & Co. by a woman who claimed her diabetes was caused by Zyprexa is time-barred under California law


Lilly's Zyprexa Warnings Were Adequate, Federal Judge Rules

Eli Lilly & Co. adequately warned doctors of the metabolic risks associated with Zyprexa use, a federal judge ruled


Learned Intermediary Doctrine Defeats Failure-To-Warn Claims

The learned intermediary doctrine defeats allegations that Eli Lilly & Co. failed to warn that combining Zyprexa with Celexa could have fatal results


Learned Intermediary Doctrine Defeats Zyprexa Claims

The learned intermediary doctrine bars claims that Eli Lilly & Co.'s Zyprexa caused a man to develop diabetes because he failed to present evidence that


Name-Brand Drug Makers Had No Duty to Warn of Risks, Judge Rules

The makers of Reglan had no duty under Texas law to warn of the risks associated with the drug's generic counterpart


Past Issues:


VERDICTRACK

The HarrisMartin VerdicTrack lets you track verdicts by product, state, defendant, or expert.

  • DEFENDANT
  • DISEASE / INJURY
  • PRODUCT
  • PUBLICATION
  • STATE
  • SEARCH BY EXPERT